IL302383A - Method of safe administration of anti-tau antibody - Google Patents

Method of safe administration of anti-tau antibody

Info

Publication number
IL302383A
IL302383A IL302383A IL30238323A IL302383A IL 302383 A IL302383 A IL 302383A IL 302383 A IL302383 A IL 302383A IL 30238323 A IL30238323 A IL 30238323A IL 302383 A IL302383 A IL 302383A
Authority
IL
Israel
Prior art keywords
seq
amino acid
acid sequence
tau
chain variable
Prior art date
Application number
IL302383A
Other languages
English (en)
Hebrew (he)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of IL302383A publication Critical patent/IL302383A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
IL302383A 2020-10-26 2021-10-25 Method of safe administration of anti-tau antibody IL302383A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063105810P 2020-10-26 2020-10-26
US202163250114P 2021-09-29 2021-09-29
PCT/EP2021/079566 WO2022090169A1 (en) 2020-10-26 2021-10-25 Method of safe administration of anti-tau antibody

Publications (1)

Publication Number Publication Date
IL302383A true IL302383A (en) 2023-06-01

Family

ID=78483271

Family Applications (1)

Application Number Title Priority Date Filing Date
IL302383A IL302383A (en) 2020-10-26 2021-10-25 Method of safe administration of anti-tau antibody

Country Status (10)

Country Link
US (1) US20220127346A1 (https=)
EP (1) EP4232472A1 (https=)
JP (1) JP2023546503A (https=)
KR (1) KR20230097110A (https=)
AU (1) AU2021370222A1 (https=)
CA (1) CA3199808A1 (https=)
IL (1) IL302383A (https=)
MX (1) MX2023004832A (https=)
TW (1) TW202231661A (https=)
WO (1) WO2022090169A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3093200A1 (en) 2018-03-05 2019-09-12 Janssen Pharmaceutica Nv Anti-phf-tau antibodies and uses thereof
US20230235034A1 (en) * 2020-05-26 2023-07-27 The Trustees Of The University Of Pennsylvania Monoclonal antibodies against pathological tau, and methods using same
CA3199806A1 (en) * 2020-10-26 2022-05-05 Janssen Pharmaceutica Nv Methods of reducing tau in human subjects

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
TWI771389B (zh) * 2017-03-16 2022-07-21 美商健生生物科技公司 抗phf-tau抗體及其用途
US10646569B2 (en) * 2017-05-16 2020-05-12 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity

Also Published As

Publication number Publication date
CA3199808A1 (en) 2022-05-05
AU2021370222A1 (en) 2023-06-22
KR20230097110A (ko) 2023-06-30
WO2022090169A1 (en) 2022-05-05
JP2023546503A (ja) 2023-11-02
TW202231661A (zh) 2022-08-16
US20220127346A1 (en) 2022-04-28
EP4232472A1 (en) 2023-08-30
MX2023004832A (es) 2023-07-18

Similar Documents

Publication Publication Date Title
JP2024037893A (ja) アルツハイマー病治療方法
IL302383A (en) Method of safe administration of anti-tau antibody
US20240148782A1 (en) Treatment and prevention of alzheimer's disease (ad)
US20220062412A1 (en) Treatment of alzheimer's disease (ad) with an aluminum salt
TW202334201A (zh) 抗Ｔａｕ抗體之組成物、劑型及方法
JP2023548005A (ja) 抗トランスサイレチン抗体およびその使用方法
TW202543674A (zh) 抗N3pGlu類澱粉蛋白β抗體、其劑量及其用途
US20250051427A1 (en) Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody
US20220127345A1 (en) Methods of Reducing Tau in Human Subjects
TW202328178A (zh) 抗Ａβ初原纖維抗體的皮下配製物及其使用方法
US20250011417A1 (en) Methods for the treatment of thyroid eye disease
CN117999094A (zh) 抗Aβ初原纤维抗体的皮下配制品及其使用方法
EA051320B1 (ru) Способ безопасного введения антитела к тау-белку
CN116829582A (zh) 安全施用抗Tau抗体的方法
HK40100358A (zh) 安全施用抗tau抗体的方法
TW202513583A (zh) 使用抗Ａβ初原纖維抗體之治療方法
Class et al. Patent application title: Methods of Reducing Tau in Human Subjects
HK40100364A (zh) 减少人类受试者中的tau的方法
EA052839B1 (ru) Способы снижения уровня тау-белка у человеческих индивидов